DOCSLIB.ORG

Basic Screen Data: 6.2.1 in Data Analysis, Load Two Files

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Basic Screen Data: 6.2.1 in Data Analysis, Load Two Files Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19 1.0 Purpose 1.1 This document describes procedures employed by the Forensic Toxicology Laboratory to screen blood or other biological specimens for the presence of alkaline-extractable (basic) drugs. 1.2 Biological specimens are basified to a moderately alkaline pH 9.3 at which basic drugs are soluble in organic solvent. The organic layer is separated and the basic drugs are back extracted into 2 N HCl. The acid layer is then made alkaline and basic drugs are re-extracted into an organic solvent. The extracts are analyzed by gas chromatography mass spectrometry (GC/MS) operating in full scan mode. 2.0 Scope 2.1 The assay is appropriate for qualitative detection of chromatographically stable alkaline extractable drugs in whole blood, serum, plasma, urine, bile, stomach contents or tissue homogenates. This methodd could Copyalso be applied to non- biological samples. 3.0 Definitions and Abbreviations 3.1 No method-specific or nonrolle-standard terms are used in this procedure. 4.0 Materials t 4.1 Instruments and Equipment 4.1.1 13 x 100 mm screw top test tubes 4.1.2 Teflon screw caps 4.1.3 Autosampler vials and caps Uncon4.1.4 100 µL Syringe 4.1.5 Vacuum Pump 4.1.6 GC/MS 4.1.7 Varian Factor 4 VF-5MS (15 m x 0.25 mm x 0.25 µm) GC column or equivalent 4.2 Reagents Page 1 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19 4.2.1 Ammonium Hydroxide, Reagent Grade 4.2.2 n-Butyl Chloride (chlorobutanes), HPLC Grade 4.2.3 Saturated Sodium Borate Buffer, pH 9.3 A. To 1000 mL of deionized (DI) water, add sodium borate until no more sodium borate will dissolve. B. Stable for 6 months at room temperature. 4.2.4 Dichloromethane (methylene chloride), HPLC Grade 4.2.5 2 N HCl A. Add 166 mL of concentrated HCl to 500Copy mL deionized water and mix. B. Allow to cool to room temperature. QS to 1000 mL with DI water. C. Stir to mix. D. Stable at room temperature indefinitely. 4.2.6 Methanol, HPLC grade 4.3 Stock Standards and Controls Note: Certified reference materials shall be used within manufacturer’s expiration date and shall be stored at the recommended storage temperature. Note: Alternate vendors may be used as long as standards are equivalent. 4.3.1 Commercially prepared stock solutions Analyte Vendor Catalog Concentration Number Methamphetamine Cerilliant M-009 1.0 mg/mL Diphenhydramine Cerilliant D-015 1.0 mg/mL Chlorpheniramine Cerilliant C-036 1.0 mg/mL UncontrolledCodeine Cerilliant C-006 1.0 mg/mL Hydrocodone Cerilliant H-003 1.0 mg/mL Verapamil Cerilliant V-002 1.0 mg/mL Methadone Cerilliant M-007 1.0 mg/mL Lidocaine Cerilliant L-018 1.0 mg/mL Cocaine Cerilliant C-008 1.0 mg/mL Tramadol Cerilliant T-027 1.0 mg/mL Amitryptyline Cerilliant A-923 1.0 mg/mL Diazepam Cerilliant D-907 1.0 mg/mL Diltiazem Cerilliant D-035 1.0 mg/mL Page 2 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19 Phencyclidine Cerilliant P-007 1.0 mg/mL Doxylamine Cerilliant D-045 1.0 mg/mL Venlafaxine Cerilliant V-004 1.0 mg/mL Dextromethorphan Cerilliant D-013 1.0 mg/mL Propoxyphene Cerilliant P-011 1.0 mg/mL Nordiazepam Cerilliant N-905 1.0 mg/mL Mirtazapine Cerilliant M-128 1.0 mg/mL Trazodone Cerilliant T-030 1.0 mg/mL Cyclobenzaprine Cerilliant C-060 1.0 mg/mL Oxycodone Cerilliant O-002 1.0 mg/mL Zolpidem Cerilliant Z-901 1.0 mg/mL Norsertraline Cerilliant N-049 0.10 mg/mL Nortriptyline Cerilliant N-907 1.0 mg/mL Sertraline Cerilliant CopyS-021 1.0 mg/mL Citalopram Cerilliant C-095 1.0 mg/mL Meprobamate Cerilliant M-039 1.0 mg/mL Carisoprodol Cerilliant C-077 1.0 mg/mL Alprazolam Cerilliant A-903 1.0 mg/mL Levamisole Cerilliant L-025 1.0 mg/mL Fentanyl Cerilliant F-002 0.10 mg/mL 4.3.2 Promethazine Stock Solution 1.0 mg/mL A. Weigh 11.3 mg of Promethazine HCl into a 10 mL volumetric flask. B. Adjust volume to 10 mL with methanol. C. Stable for 1 year at -10 to -20º C. D. Alternatively, a 1.0 mg/mL prepared promethazine solution may be substituted. (i.e., Cerilliant catalog #P-111 or equivalent) 4.3.3 Internal Standard Stock, SKF-525A 1.0 mg/mL A. Weigh 10 mg SKF-525A (proadifen hydrochloride) and dilute to 10 mL with methanol. B. Stable for 3 years at -10 to -20º C. Uncontrolled4.4 Working Standards and Controls 4.4.1 Working Positive Basic Control #1 0.01/0.004 mg/mL A. Pipette 100 µL of codeine, cyclobenzaprine, diphenhydramine, methadone, methamphetamine, verapamil, and zolpidem to a 10 mL volumetric flask. B. Pipette 40 µL of chlorpheniramine, hydrocodone, and oxycodone to the same volumetric flask. C. Dilute to 10 mL with methanol. Stable until the earliest manufacturer’s expiration date at -10 to -20º C. Page 3 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19 4.4.2 Working Positive Basic Control #2 0.01 mg/mL A. Pipette 100 µL of amitriptyline, cocaine, diazepam, diltiazem, lidocaine, nortriptyline, promethazine, sertraline, and tramadol to a 10 mL volumetric flask. B. Dilute to 10 mL with methanol. C. Stable until the earliest manufacturer’s expiration date at -10 to -20º C. 4.4.3 Working Positive Basic Control #3 0.01/0.004 mg/mL A. Pipette 100 µL of nordiazepam, doxylamine, mirtazapine, phencyclidine, propoxyphene, trazodone, venlafaxine and citalopram to a 10 mL volumetric flask. B. Pipette 1 mL of norsertraline into the same volumetric flask. C. Pipette 40 µL of dextromethorphan into the same volumetric flask. D. Dilute to 10 mL with methanol. Copy E. Stable until the earliest manufacturer’s expiration date at -10 to -20º C. 4.4.4 Working Positive Basic Control #4 0.01/0.0008 mg/mL A. Pipette 100 µL of alprazolam and levamisole to a 10 mL volumetric flask. B. Pipette 80 µL of fentanyl into the same 10 mL volumetric flask. C. Dilute to 10 mL with methanol. D. Stable until the earliest manufacturer’s expiration date at -10 to -20º C. 4.4.5 Working Internal Standard SKF-525A 0.10 mg/mL A. Transfer 1 mL of stock internal standard to a 10 mL volumetric flask. B. Adjust the volume to 10 mL with methanol. C. Stable for 6 months at -10 to -20º C. 5.0 Procedure 5.1 Control and case sample preparation 5.1.1 Label sufficient 13 x 100 mm screw top test tubes for reagent blank, negative control, positive controls, and case samples. Uncontrolled5.1.2 Basic Blood Control #1 A. Add 50 µL of working positive basic control #1 to the appropriately labeled tube. Do not dry as methamphetamine will be lost. 5.1.3 Basic Blood Control #2 A. Add 50 µL of working positive basic control #2 to the appropriately labeled tube. Do not dry. 5.1.4 Basic Blood Control #3 A. Add 50 µL of working positive basic control #3 to the Page 4 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19 appropriately labeled tube. Do not dry. 5.1.5 Basic Blood Control #4 A. Add 50 µL of working positive basic control #4 to the appropriately labeled tube. B. Add 50 µL of meprobamate stock control to the same test tube. C. Add 20 µL of carisoprodol stock control to the same test tube. D. Do not dry. Note: Other drugs may be used to prepare additional controls as necessary. Prepare using 0.01mg/mL concentration if available. 5.1.6 Pipette 2 mL of blank blood into reagent blank, negative control and positive control tubes. Copy 5.1.7 Pipette 2 mL of case specimen into the appropriately labeled tube. 5.1.8 Add 20 µL of 0.10 mg/mL SKF working internal standard into all tubes except reagent blank and vortex. 5.2 Extraction 5.2.1 Add 500 µL of saturated sodium borate and 5 mL of n-butyl chloride. A. In severely decomposed cases or tissues, 100 µL of NH4OH may replace saturated borate to perform a strong basic extraction. Add a set of positive controls and a negative control to be extracted with NH4OH replacement. 5.2.2 Cap and mix on rocker for 15 minutes. 5.2.3 Centrifuge tubes for 5 minutes at 3000 rpm. 5.2.4 Transfer upper organic layer into clean, labeled 13 x 100 mm screw top tube. Uncontrolled 5.2.5 Add 2 mL of 2N HCl. 5.2.6 Cap and mix on rocker for 15 minutes. 5.2.7 Centrifuge tubes for 5 minutes at 3000 rpm. 5.2.8 Discard upper organic layer.
Load more

Recommended publications
  • Basic Quant GCMS
    Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Toxicology Manager Document Type: GC & GC/MS Procedure No.: TOX07.3005 Title: Quantitation of basic drugs by gas chromatography / mass spectrometry Rev.:15 1.0 Purpose 1.1 This document describes the procedures used by the Toxicology Laboratory to quantitate basic drugs using gas chromatography/mass spectrometry. 1.2 Biological specimens are basified to the moderately alkaline pH 9 at which basic compounds are in an unionized form and are soluble in an organic solvent. After liquid/liquid extraction, the organic layer is separated and the compound X is back extracted into 2 N HCl. The acid layer is then made alkaline and compound X is re-extracted into an organic solvent. 2.0 Scope 2.1 The assay is appropriate for quantitation of any basic compound (X) in blood including serum and plasma, urine, bile, stomach contents or tissue homogenates. 3.0 Definitions and Abbreviations 3.1 No method-specific or non-standard terms are used in this procedure. 4.0 Materials 4.1 Instruments and Equipment 4.1.1 13 x 100 mm screw top tubes and caps 4.1.2 Mixer 4.1.3 Rocker 4.1.4 Centrifuge 4.1.5 Transfer pipettes 4.1.6 Autosampler vials and rubber septum caps 4.1.7 Autosampler vial inserts 4.1.8 Vial crimper 4.1.9 100uL syringe 4.1.10 GC/MS Uncontrolled4.2 Reagents Copy 4.2.1 Ammonium Hydroxide Reagent Grade 4.2.2 n-Butyl chloride (chlorobutane) HPLC Grade 4.2.3 Saturated Sodium Borate Buffer, pH 9.3 A.
    [Show full text]
  • Seminar on Drug Chirality
    Drug chirality: Stereoselectivity in the action and disposition of anaesthetic agents Isomerism Isomers: Drugs with the same chemical composition and molecular formula. Isomers Structural Stereoisomers isomers •Constitutional / Structural isomerism: Same molecular formula but different chemical structure as the arrangement of atoms is different. Stereoisomerism: Same molecular formula and chemical structure but a different configuration (i.e. different three dimensional spatial arrangement of their atoms) Two types: 1. Optical isomers 2. Geometrical isomers Optical isomerism Enantiomers: A pair of stereoisomers that are non-superimposable mirror images of each other. Cause of enantiomerism: presence of a chiral centre. Physiochemical properties ( solubility, melting and boiling points, ionization constant) are identical. Separation is difficult. Diastereomers: Stereoisomers that are not mirror images of each other and are not enantiomeric. Physiochemical properties are different. Separation is easy. What is chirality? Chiral - derived from a Greek word chiros, meaning handedness. A molecule or object that is not superimposable on its mirror image is said to be chiral. Chiral centre / asymmetric carbon / stereogenic centre – A carbon atom attached to four different substituents. • Achiral molecules usually contain a plane of symmetry but chiral molecules do not. • A plane of symmetry is a mirror plane that cuts the molecule in half, so that one half of the molecule is a reflection of the other half. • With chiral compounds, the plane of the polarized light is rotated through an angle . A compound that rotates polarized light is said to be optically active. •With achiral compounds, the light that passes through the compound remains unchanged. A compound that does not change the plane of polarized light is said to be optically inactive.
    [Show full text]
  • Consensus for the Management of Analgesia, Sedation and Delirium in Adults with COVID-19-Associated Acute Respiratory Distress Syndrome
    ARTIGO ESPECIAL Manuel Donato1,2,3 , Federico Carlos Carini4 , María Julia Meschini5, Ignacio López Saubidet6 , Consenso para el manejo de la analgesia, sedación Adela Goldberg7, Marisol García Sarubio5, Daniela Olmos8, Rosa Reina5 em nombre del Comité de y delirium en adultos con síndrome de distrés Analgesia, Sedación y Delirium de la Sociedad Argentina de Terapia Intensiva respiratorio agudo por COVID-19 Consensus for the management of analgesia, sedation and delirium in adults with COVID-19-associated acute respiratory distress syndrome 1. Hospital General de Agudos José María Penna RESUMEN Sedación y Delirium de la Sociedad - Buenos Aires, Argentina. Argentina de Terapia Intensiva. 2. Ministerio de Salud de la Nación Argentina – Objetivo: Proponer estrategias Resultados: Se acordaron Buenos Aires, Argentina. agile para este abordaje integral de 3. Instituto de Efectividad Clínica y Sanitaria - recomendaciones y se desarrollaron la analgesia, sedación, delirium, Buenos Aires, Argentina. herramientas para asegurar un 4. Hospital Italiano de Buenos Aires - Buenos implementación de movilidad abordaje integral de analgesia, Aires, Argentina. temprana e inclusión familiar del sedación, delirium, implementación 5. Hospital Interzonal General de Agudos General paciente con síndrome de dificultad San Martín - La Plata, Argentina. de movilidad temprana e inclusión respiratoria aguda por COVID-19, 6. Centro de Educación Médica e Investigaciones familiar del paciente adulto con Clínicas “Norberto Quirno” - Buenos Aires, Argentina. considerando el alto riesgo de infección síndrome de dificultad respiratoria 7. Sanatorio de La Trinidad Mitre - Buenos Aires, que existe entre los trabajadores de Argentina. aguda por COVID-19. salud, el tratamiento humanitario 8. Hospital Municipal Príncipe de Asturias - Córdoba, Discusión: Ante el nuevo orden Argentina.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • Test Summary Sheet For
    Test Summary Sheet for: 8054B Postmortem, Expanded with NPS, Blood (Forensic) The following test codes are contained in this document: 1. 8054B Postmortem, Expanded with NPS, Blood (Forensic) 2. 50000B Acetaminophen Confirmation, Blood (Forensic) 3. 52250B Alcohols and Acetone Confirmation, Blood (Forensic) 4. 52143B Alfentanil and Sufentanil Confirmation, Blood (Forensic) 5. 52168B Amitriptyline and Metabolite Confirmation, Blood (Forensic) 6. 52239B Amoxapine Confirmation, Blood (Forensic) 7. 52485B Amphetamines Confirmation, Blood (Forensic) 8. 52416B Aripiprazole Confirmation, Blood (Forensic) 9. 52007B Atomoxetine Confirmation, Blood (Forensic) 10. 50011B Barbiturates Confirmation, Blood (Forensic) 11. 52365B Bath Salts Confirmation, Blood (Forensic) 12. 52367B Bath Salts Confirmation, Blood (Forensic) 13. 50012B Benzodiazepines Confirmation, Blood (Forensic) 14. 52443B Benztropine Confirmation, Blood (Forensic) 15. 52245B Brompheniramine Confirmation, Blood (Forensic) 16. 52011B Bupivacaine Confirmation, Blood (Forensic) 17. 52012B Bupropion and Metabolite Confirmation, Blood (Forensic) 18. 52444B Buspirone Confirmation, Blood (Forensic) 19. 52198B Cannabinoids Confirmation, Blood (Forensic) 20. 52015B Carbamazepine and Metabolite Confirmation, Blood (Forensic) 21. 52017B Carisoprodol and Metabolite Confirmation, Blood (Forensic) 22. 52440B Chlorpheniramine Confirmation, Blood (Forensic) 23. 52272B Chlorpromazine Confirmation, Blood (Forensic) 24. 52482B Citalopram Confirmation, Blood (Forensic) 25. 52274B Clomipramine and Metabolite
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0033522 A1 Wainer Et Al
    US 20050033522A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0033522 A1 Wainer et al. (43) Pub. Date: Feb. 10, 2005 (54) COMPUTER-BASED MODEL FOR Related U.S. Application Data IDENTIFICATION AND CHARACTERIZATION OF (63) Continuation-in-part of application No. 10/411,206, NON-COMPETITIVE INHIBITORS OF filed on Apr. 11, 2003. NCOTINIC ACETYLCHOLINE RECEPTORS AND RELATED LIGAND-GATED ON Publication Classification CHANNEL RECEPTORS (51) Int. Cl." .......................... G06F 19/00; G01N 33/48; (76) Inventors: Irving W. Wainer, Washington, DC GO1N 33/50 (US); Krzysztof Jozwiak, Abingdon, (52) U.S. Cl. ................................................................ 702/19 MD (US); Ruin Moaddel, Germantown, MD (US); Sarangan (57) ABSTRACT Ravichandran, Frederick, MD (US); A computer readable medium holding data of a molecular Jack R. Collins, Frederick, MD (US) model of a ligand-gated ion channel receptor and/or a computer System for modeling Said receptor are provided by Correspondence Address: the instant invention. The molecular model can be used to BRCH STEWART KOLASCH & BRCH design novel compounds having activity as non-competitive PO BOX 747 inhibitors of the ion channel. A preferred embodiment of the FALLS CHURCH, VA 22040-0747 (US) invention relates to nicotinic acetylcholine receptorS. Com pounds having activity as non-competitive inhibitors of (21) Appl. No.: 10/820,809 ligand-gated ion channel receptors and methods for inhib iting the receptor and treating diseases or disorderS mediated (22) Filed: Apr. 9, 2004 by function of the receptor are also disclosed. Patent Application Publication Feb. 10, 2005 Sheet 1 of 16 US 2005/0033522 A1 ONE SUBUNT OF nAChR - N NH2 UGAND-BINDING STE Soffee CROSS-SECTION OF FME ASSEMBLED SUBUNITS (2xa + 3x p) OF nAChR i: T.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Chronic Venous Insufficiency/CVI
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Chronic Venous Insufficiency/CVI Chemical Activity Count (+)-AROMOLINE 1 (+)-CATECHIN 5 (+)-GALLOCATECHIN 1 (+)-HERNANDEZINE 1 (+)-PRAERUPTORUM-A 1 (+)-SYRINGARESINOL 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (-)-ACETOXYCOLLININ 1 (-)-APOGLAZIOVINE 1 (-)-BISPARTHENOLIDINE 1 (-)-BORNYL-CAFFEATE 1 (-)-BORNYL-FERULATE 1 (-)-BORNYL-P-COUMARATE 1 (-)-CANADINE 1 (-)-EPICATECHIN 4 (-)-EPICATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN 1 (-)-EPIGALLOCATECHIN-3-O-GALLATE 2 (-)-EPIGALLOCATECHIN-GALLATE 3 (-)-HYDROXYJASMONIC-ACID 1 (-)-N-(1'-DEOXY-1'-D-FRUCTOPYRANOSYL)-S-ALLYL-L-CYSTEINE-SULFOXIDE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 1 (2R)-(12Z,15Z)-2-HYDROXY-4-OXOHENEICOSA-12,15-DIEN-1-YL-ACETATE 1 (7R,10R)-CAROTA-1,4-DIENALDEHYDE 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 1 1,2,6-TRI-O-GALLOYL-BETA-D-GLUCOSE 1 1,7-BIS(3,4-DIHYDROXYPHENYL)HEPTA-4E,6E-DIEN-3-ONE 1 Chemical Activity Count 1,7-BIS(4-HYDROXY-3-METHOXYPHENYL)-1,6-HEPTADIEN-3,5-DIONE 1 1,8-CINEOLE 1 1-(METHYLSULFINYL)-PROPYL-METHYL-DISULFIDE 1 1-ETHYL-BETA-CARBOLINE 1 1-O-(2,3,4-TRIHYDROXY-3-METHYL)-BUTYL-6-O-FERULOYL-BETA-D-GLUCOPYRANOSIDE 1 10-ACETOXY-8-HYDROXY-9-ISOBUTYLOXY-6-METHOXYTHYMOL 1 10-GINGEROL 1 12-(4'-METHOXYPHENYL)-DAURICINE 1 12-METHOXYDIHYDROCOSTULONIDE 1 13',II8-BIAPIGENIN 1 13-HYDROXYLUPANINE 1 14-ACETOXYCEDROL 1 14-O-ACETYL-ACOVENIDOSE-C 1 16-HYDROXY-4,4,10,13-TETRAMETHYL-17-(4-METHYL-PENTYL)-HEXADECAHYDRO- 1 CYCLOPENTA[A]PHENANTHREN-3-ONE 2,3,7-TRIHYDROXY-5-(3,4-DIHYDROXY-E-STYRYL)-6,7,8,9-TETRAHYDRO-5H-
    [Show full text]
  • Analytical Separations Using Packed and Open-Tubular Capillary Electrochromatography" (2004)
    Louisiana State University LSU Digital Commons LSU Doctoral Dissertations Graduate School 2004 Analytical separations using packed and open- tubular capillary electrochromatography Constantina P. Kapnissi Louisiana State University and Agricultural and Mechanical College, [email protected] Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations Part of the Chemistry Commons Recommended Citation Kapnissi, Constantina P., "Analytical separations using packed and open-tubular capillary electrochromatography" (2004). LSU Doctoral Dissertations. 595. https://digitalcommons.lsu.edu/gradschool_dissertations/595 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please [email protected]. ANALYTICAL SEPARATIONS USING PACKED AND OPEN- TUBULAR CAPILLARY ELECTROCHROMATOGRAPHY A Dissertation Submitted to the Graduate Faculty of the Louisiana State University and Agricultural and Mechanical College in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Department of Chemistry by Constantina P. Kapnissi B.S., University of Cyprus, 1999 August 2004 Copyright 2004 Constantina Panayioti Kapnissi All rights reserved ii DEDICATION I would like to dedicate this work to my husband Andreas Christodoulou, my parents Panayiotis and Eleni Kapnissi, and my sisters Erasmia, Panayiota and Stella Kapnissi. I want to thank all of you for helping me, in your own way, to finally make one of my dreams come true. Thank you for encouraging me to continue and achieve my goals. Thank you for your endless love, support, and motivation. Andreas, thank you for your continuous patience and for being there for me whenever I needed you during this difficult time.
    [Show full text]
  • Handbook of Drugs in Intensive Care: an A
    This page intentionally left blank This page intentionally left blank Handbook of Drugs in Intensive Care Fourth edition This book is dedicated to Georgina Paw Handbook of Drugs in Intensive Care An A-Z Guide Fourth edition Henry G W Paw BPharm MRPharmS MBBS FRCA Consultant in Anaesthesia and Intensive Care York Hospital York Rob Shulman BSc (Pharm) MRPharmS Dip Clin Pham, DHC (Pharm) Lead Pharmacist in Critical Care University College London Hospitals London CAMBRIDGE UNIVERSITY PRESS Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo, Delhi, Dubai, Tokyo Cambridge University Press The Edinburgh Building, Cambridge CB2 8RU, UK Published in the United States of America by Cambridge University Press, New York www.cambridge.org Information on this title: www.cambridge.org/9780521757157 © H. Paw and R. Shulman 2010 This publication is in copyright. Subject to statutory exception and to the provision of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press. First published in print format 2010 ISBN-13 978-0-521-75715-7 Paperback Cambridge University Press has no responsibility for the persistence or accuracy of urls for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate. CONTENTS Introduction vii How to use this book viii Abbreviations x Acknowledgements xiii DRUGS: An A–Z Guide 1 SHORT NOTES 229 Routes of
    [Show full text]
  • ECO Cup One Step Drug Test Forensic Insert
    paranoia, hallucinations, and psychotic behavior. The effects of Amphetamines generally last 2-4 unconsciousness. hours following use, and the drug has a half-life of 4-24 hours in the body. About 30% of Cocaine is often self-administered by nasal inhalation, intravenous injection and free-base Amphetamines are excreted in the urine in unchanged form, with the remainder as hydroxylated smoking. It is excreted in the urine in a short time primarily as Benzoylecgonine. 1.2 and deaminated derivatives. Benzoylecgonine, a major metabolite of cocaine, has a longer biological half-life (5-8 hours) than 2 The ECO CUP™ One Step Drug Test yields a positive result when the concentration of Amphetamine cocaine (0.5-1.5 hours), and can generally be detected for 24-48 hours after cocaine exposure. in urine exceeds 1,000 ng/mL. This is the suggested screening cut-off for positive specimens The ECO CUP™ One Step Drug Test yields a positive result when the concentration of Benzoylecgonine set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).3 in urine exceeds 300 ng/mL. This is the suggested screening cut-off for positive specimens set by One Step Drug Test the Substance Abuse and Mental Health Services Administration (SAMHSA, USA). 3 Package Insert for Multi Drug Screen Test Cup AMPHETAMINE (AMP 500) COCAINE (COC 150) This Instruction Sheet is for testing of any combination of the following drugs: See AMPHETAMINE (AMP 1000) for the summary. See COCAINE (COC 300) for the summary. AMP/BAR/BZO/BUP/COC/THC/MTD/mAMP/MDMA/MOR/OPI/OXY/PCP/PPX/TCA/EDDP/6-ACM/ETG The ECO CUP™ One Step Drug Test yields a positive result when the concentration of The ECO CUP™ One Step Drug Test yields a positive result when the concentration of Including Adulterant Tests (Specimen Validity Tests) for: Amphetamine in urine exceeds 500 ng/mL.
    [Show full text]
  • Alltech® Drug Standards for the Forensic, Clinical & Pharmaceutical Industries OH
    Alltech® Drug Standards For the Forensic, Clinical & Pharmaceutical Industries OH H3C H H H3C H HO Catalog #505B Our Company Welcome to the Grace's Alltech® Drug Standards Catalog W. R. Grace has manufactured high-quality silica for over 150 years. Grace has been behind the scenes for the past 30 years supplying silica to the chromatography industry. Now we’re in the forefront moving beyond silica, developing and delivering innovative complementary products direct to the customer. Grace Davison Discovery Sciences was founded on Grace’s core strength as a premier manufacturer of differentiated media for SPE, Flash, HPLC, and Process chromatography. This core competency is further enhanced by bringing seven well-known global separations companies together, creating a powerful new single source for all your chromatography needs. A Full Portfolio of Chromatography Products to Support Drug Standards: • HPLC Columns • HPLC Accessories • Flash Products • TLC Products • GC Columns • GC Accessories • SPE and Filtration • Equipment • Syringes • Tubing • Vials For complete details, download the Chromatography Essentials catalog from the Grace web site or contact your customer service representative. Alltech - Part of the Grace Family of Products In 2004, Alltech Associates Inc. was acquired by Grace along with the Alltech® Drug Standards product line. Through investment in research and strategic acquisitions, Grace has expanded our product range and global reach while drawing upon the support of the Grace corporate infrastructure and more than 6000 employees globally to support scientific research and analysis worldwide. With key manufacturing sites in North and South America, Europe, and Asia, plus an extensive international sales and distribution network, separation scientists throughout the world can count on timely delivery and expert local technical service.
    [Show full text]
  • The Sigma1 Protein As a Target for the Non-Genomic Effects of Neuro(Active)Steroids: Molecular, Physiological, and Behavioral Aspects François P
    J Pharmacol Sci 100, 93 – 118 (2006) Journal of Pharmacological Sciences ©2006 The Japanese Pharmacological Society Critical Review The Sigma1 Protein as a Target for the Non-genomic Effects of Neuro(active)steroids: Molecular, Physiological, and Behavioral Aspects François P. Monnet1 and Tangui Maurice2,* 1Unité 705 de l’Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 7157 du Centre National de la Recherche Scientifique, Université de Paris V et VII, Hôpital Lariboisière-Fernand Widal, 2, rue Ambroise Paré, 75475 Paris cedex 10, France 2Unité 710 de l’Institut National de la Santé et de la Recherche Médicale, Ecole Pratique des Hautes Etudes, Université de Montpellier II, cc 105, place Eugène Bataillon, 34095 Montpellier cedex 5, France Received December 15, 2005 Abstract. Steroids synthesized in the periphery or de novo in the brain, so called ‘neuro- steroids’, exert both genomic and nongenomic actions on neurotransmission systems. Through rapid modulatory effects on neurotransmitter receptors, they influence inhibitory and excitatory neurotransmission. In particular, progesterone derivatives like 3α-hydroxy-5α-pregnan-20-one (allopregnanolone) are positive allosteric modulators of the γ-aminobutyric acid type A (GABAA) receptor and therefore act as inhibitory steroids, while pregnenolone sulphate (PREGS) and dehydroepiandrosterone sulphate (DHEAS) are negative modulators of the GABAA receptor and positive modulators of the N-methyl-D-aspartate (NMDA) receptor, therefore acting as excitatory neurosteroids. Some steroids also interact with atypical proteins, the sigma (σ) receptors. Recent studies particularly demonstrated that the σ1 receptor contributes effectively to their pharmaco- logical actions. The present article will review the data demonstrating that the σ1 receptor binds neurosteroids in physiological conditions.
    [Show full text]